Table 1:
Baseline demographics and disease characteristics
| CRT (n=456) | CRT+ACT (n=463) | |
|---|---|---|
| Age, years | 45 (38–54) | 46 (37–55) |
| ECOG Performance status | ||
| 0 | 344 (75%) | 337 (73%) |
| 1 | 94 (21%) | 117 (25%) |
| 2 | 18 (4%) | 9 (2%) |
| Race/Ethnicity * | ||
| White/Caucasian | 326 (72%) | 337 (73%) |
| Black or African American | 68 (15%) | 53 (11%) |
| Asian | 22 (5%) | 31 (7%) |
| Aboriginal or Pacific Islander | 11 (2%) | 13 (3%) |
| Other | 28 (6%) | 29 (6%) |
| Region | ||
| Australia and New Zealand | 84 (18%) | 81 (17%) |
| USA and Canada | 366 (80%) | 373 (81%) |
| Rest of the World | 6 (1%) | 9 (2%) |
| Tobacco smoking | ||
| Never Smoker | 237 (52%) | 224 (48%) |
| Current or Ex-Smoker or Unknown | 219 (48%) | 239 (52%) |
| Histological type | ||
| Squamous cell carcinoma | 358 (79%) | 383 (83%) |
| Adenocarcinoma | 79 (17%) | 68 (15%) |
| Adenosquamous | 19 (4%) | 12 (3%) |
| FIGO stage (2008) | ||
| 1B1 (all node positive), 1B2 or IIA | 152 (33%) | 154 (33%) |
| IIB | 196 (43%) | 197 (43%) |
| IIIB or IVA | 108 (24%) | 112 (24%) |
| Maximum tumour diameter, cm | 5.0 (4–6) | 5.0 (4–6) |
| Nodal involvement | ||
| Pelvic alone | 144 (32%) | 149 (32%) |
| Common iliac alone | 33 (7%) | 31 (7%) |
| Pelvic and common iliac | 44 (10%) | 44 (10%) |
| Neither | 225 (49%) | 231 (50%) |
| Unknown | 10 (2%) | 8 (2%) |
| Extended field planned | ||
| No | 397 (87%) | 404 (87%) |
| Yes | 59 (13%) | 59 (13%) |
Data are median (Q1–Q3) or n (%). CRT=Chemoradiation therapy. ACT=adjuvant chemotherapy. ECOG=Eastern Cooperative Oncology Group. FIGO=International Federation of Gynecology and Obstetrics.
*
Self-reported